Onconetix shares surge 19.91% on Realbotix robot delivery to Ericsson amid pending acquisition.

Onconetix Inc. surged 19.91% in intraday trading following a press release highlighting Realbotix's delivery of its first Vinci-equipped humanoid robot to Ericsson. The announcement reinforces the strategic value of Realbotix, a pending acquisition target for Onconetix, by showcasing the commercial viability of its patented AI vision technology capable of real-time engagement tracking. Investors appear to view the successful deployment as validation of the anticipated all-stock merger, which is expected to close in the second half of 2026, thereby boosting confidence in Onconetix's pivot toward AI-driven medical technology solutions.